Under Consent Decree, J&J Delays Full Return Of Recalled OTCs Until 2012
This article was originally published in The Tan Sheet
Executive Summary
Johnson & Johnson pushes back to 2012 the target for returning its full slate of recalled OTC drugs to market as it adjusts to operating under a consent decree with FDA and the Department of Justice.
You may also be interested in...
J&J Promotes Preventive Care, Wellness In US Health Debate
OTC makers' stakes include loosening rules on paying for consumer products with pre-tax savings and encouragement of self-care to maintain wellness.
J&J Promotes Preventive Care, Wellness In US Health Debate
OTC makers' stakes include loosening rules on paying for consumer products with pre-tax savings and encouragement of self-care to maintain wellness.
J&J Invests In Consumer Business For Long Haul, Not Quick Sale
"We believe the consumer business at J&J is an absolute integral part of our company," says CEO Alex Gorsky.